Search

Displaying results 1491 - 1500 of 1777 in total
  1. Drug

    Delandistrogene moxeparvovec

    go.drugbank.com/drugs/DB16802
    ApprovedInvestigational

    It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD).

  2. Drug

    Tabelecleucel

    go.drugbank.com/drugs/DB17072
    ApprovedInvestigational

    [L43557] The FDA has granted tabelecleucel Breakthrough Therapy Designation for EBV-associated PTLD following allogeneic HCT.[L43562]

  3. Drug

    Ferric derisomaltose

    go.drugbank.com/drugs/DB15617
    ApprovedInvestigational

    Ferric derisomaltose was developed by Pharmacosmos Therapeutics ad was granted FDA approval in January 2020.

  4. Drug

    Sulisobenzone

    go.drugbank.com/drugs/DB11185
    Approved

    Sulisobenzone is approved by the FDA in concentrations of up to 10% and in Canada, is approved by Health Canada at the same concentrations [F38].

  5. Drug

    Clove oil

    go.drugbank.com/drugs/DB11338
    ApprovedNutraceutical

    The FDA categorizes clove oil as generally recognized as safe (GRAS) for use in dental cement or as a food additive [F108].

  6. Drug

    Vibrio cholerae CVD 103-HgR strain live antigen

    go.drugbank.com/drugs/DB14443
    ApprovedInvestigational

    [A244489] The FDA approved the cholera vaccine containing _Vibrio cholerae_ CVD 103-HgR strain live antigen under the brand name Vaxchora in June 2016, making it the first vaccine indicated for cholera

  7. Drug

    Vismodegib

    go.drugbank.com/drugs/DB08828
    ApprovedInvestigational

    [A258608,L45803] In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma.

  8. Drug

    Tibolone

    go.drugbank.com/drugs/DB09070
    ApprovedInvestigational

    Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for tibolone had not been approved [L1722].

  9. Drug

    Rimegepant

    go.drugbank.com/drugs/DB12457
    ApprovedInvestigational

    [L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and

  10. Drug

    Ritlecitinib

    go.drugbank.com/drugs/DB14924
    ApprovedInvestigational

    In June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older.[L47092,L47127] It was further approved by the EMA in September 2023.